



**Final Appraisal Recommendation**

Advice number: 1822 – September 2022

**Insulin degludec (Tresiba®) 100 units/ml and 200 units/ml solutions for injection in pre-filled pen, 100 units/ml solution for injection in cartridge**

**Novo Nordisk Ltd**

**Recommendation of the All Wales Medicines Strategy Group**

**Insulin degludec (Tresiba®) is recommended as an option for use within NHS Wales for the treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year.**

**Additional note(s):**

- This advice incorporates and replaces the AWMSG recommendation for insulin degludec (Tresiba®) for the treatment of diabetes mellitus in adult patients where treatment with a basal insulin analogue is considered appropriate (advice number 2816, originally published October 2016).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 5196), which includes the All Wales Toxicology and Therapeutics Centre (AWTTC) assessment form, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review after three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –  
1822

Insulin degludec (Tresiba®) 100 units/ml and 200 units/ml solutions for injection in pre-filled pen, 100 units/ml solution for injection in cartridge  
September 2022